贝利尤单抗与伏环孢素治疗美国狼疮肾炎患者的成本-效果分析
本研究构建经济学模型,基于贝利尤单抗和伏环孢素的 pivotal 临床试验数据,评估两种药物治疗狼疮肾炎的成本-效果。医疗保健视角下,贝利尤单抗的增量成本-效果比约95,000美元/质量调整生命年,伏环孢素约150,000美元/质量调整生命年;在150,000美元/质量调整生命年阈值下,两者具有成本-效果的概率分别为69%和49%。结论认为贝利尤单抗但非伏环孢素达到100,000美元/质量调整生命年的支付意愿阈值,伏环孢素的成本-效果仍存在高度不确定性。
要点
- 贝利尤单抗对比其对照组的增量成本-效果比约95,000美元/质量调整生命年。
- 伏环孢素对比其对照组的增量成本-效果比约150,000美元/质量调整生命年。
- 150,000美元/质量调整生命年阈值下,贝利尤单抗和伏环孢素具有成本-效果的概率分别为69%和49%。
核心结论
- 与各自的标准治疗组相比,贝利尤单抗但非伏环孢素达到100,000美元/质量调整生命年的支付意愿阈值。
- 尽管 informing 试验中伏环孢素可能具有临床优势,其成本-效果仍存在高度不确定性。
研究设计与样本
- 研究构建了 de novo 经济学模型,纳入完全缓解、部分缓解、活动性疾病(由 eGFR 和蛋白尿变化定义)、肾衰竭和死亡等健康状态。
- 短期数据和平均队列特征来源于贝利尤单抗的 pivotal 临床试验(Belimumab International Study in Lupus Nephritis)和伏环孢素的 pivotal 临床试验(Aurinia Urinary Protection Reduction Active-Lupus with Voclosporin trial 和 Aurinia Renal Response in Active Lupus With Voclosporin)。
- 死亡和肾衰竭风险基于已发表的 Kaplan-Meier 数据生存建模。
- 每种药物与其各自 pivotal 试验中的对照臂所代表的标准治疗进行比较,采用美国医疗保健部门视角,并探索了社会视角。
主要发现
- 医疗保健视角概率分析中,贝利尤单抗对比其对照臂的增量成本-效果比估计约为95,000美元/质量调整生命年。
- 伏环孢素对比其对照臂的相应增量比值约为150,000美元/质量调整生命年。
- 与各自标准治疗臂相比,在150,000美元/质量调整生命年阈值下,贝利尤单抗和伏环孢素具有成本-效果的概率分别为69%和49%。
- 成本-效果取决于对缓解状态生存、活动性疾病成本和效用以及缓解状态效用的假设。
- 社会视角分析中,贝利尤单抗的增量比值估计约为66,000美元/质量调整生命年,伏环孢素的增量比值估计约为133,000美元/质量调整生命年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 成本-效果取决于对缓解状态生存、活动性疾病成本和效用以及缓解状态效用的假设。
- 尽管 informing 试验中伏环孢素可能具有临床优势,其成本-效果仍存在高度不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Despite existing therapies, people with lupus nephritis progress to kidney failure and have reduced life expectancy. Belimumab and voclosporin are two new disease-modifying therapies recently approved for the treatment of lupus nephritis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A de novo economic model was developed to estimate the cost-effectiveness of these therapies, including the following health states: "complete response," "partial response," and "active disease" defined by eGFR and proteinuria changes, kidney failure, and death. Short-term data and mean cohort characteristics were sourced from pivotal clinical trials of belimumab (the Belimumab International Study in Lupus Nephritis) and voclosporin (the Aurinia Urinary Protection Reduction Active-Lupus with Voclosporin trial and Aurinia Renal Response in Active Lupus With Voclosporin). Risk of mortality and kidney failure were on the basis of survival modeling using published Kaplan-Meier data. Each drug was compared with the standard of care as represented by the comparator arm in its respective pivotal trial(s) using US health care sector perspective, with a societal perspective also explored. RESULTS: In the health care perspective probabilistic analysis, the incremental cost-effectiveness ratio for belimumab compared with its control arm was estimated to be approximately $95,000 per quality-adjusted life year. The corresponding incremental ratio for voclosporin compared with its control arm was approximately $150,000 per quality-adjusted life year. Compared with their respective standard care arms, the probabilities of belimumab and voclosporin being cost effective at a threshold of $150,000 per quality-adjusted life year were 69% and 49%, respectively. Cost-effectiveness was dependent on assumptions made regarding survival in response states, costs and utilities in active disease, and the utilities in response states. In the analysis from a societal perspective, the incremental ratio for belimumab was estimated to be approximately $66,000 per quality-adjusted life year, and the incremental ratio for voclosporin was estimated to be approximately $133,000 per quality-adjusted life year. CONCLUSIONS: Compared with their respective standard care arms, belimumab but not voclosporin met willingness-to-pay thresholds of $100,000 per quality-adjusted life year. Despite potential clinical superiority in the informing trials, there remains high uncertainty around the cost-effectiveness of voclosporin.
引用
- Mandrik O, Fotheringham J, Ren S, et al. The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States. Clin J Am Soc Nephrol. 2022. PMID: 35115304. doi:10.2215/CJN.13030921
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。